Propella Therapeutics Inc., a leader in the development of innovative best-in-class prescription products, today announced the issuance of a U.S. patent for a new drug treatment for metastatic prostate cancer. The patent covers new molecules that are designed to provide significant advantages over the current standard of care.
Do cultures influence placebo response?
A review of the high-concentration capsaicin patch and experience in its use in the management of neuropathic pain
Pharmacokinetic Analysis of Capsaicin After Topical Administration of a High-Concentration Capsaicin Patch to Patients With Peripheral Neuropathic Pain
Topical capsaicin (high concentration) for chronic neuropathic pain in adults
Pharmacokinetic and The Effect of Capsaicin in Capsicum
frutescens on Decreasing Plasma Glucose Level
frutescens on Decreasing Plasma Glucose Level
Spicy Pepper Consumption and Preferences in the United States
Capsaicin for Osteoarthritis Pain
A Comprehensive Review of the Carcinogenic and Anticarcinogenic Potential of Capsaicin
Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patch
Press Release: Propella Therapeutics Granted U.S. Patent for New Treatment for Metastatic Prostate Cancer
Propella Therapeutics Inc., a leader in the development of innovative best-in-class prescription products, today announced the issuance of a U.S. patent for a new drug treatment for metastatic prostate cancer. The patent covers new molecules that are designed to provide significant advantages over the current standard of care.